Urol. praxi, 2012; 13(3): 122-124

Intolerance to spasmolytic drugs in OAB treatment

MUDr.Martin Petzel, Ph.D., MUDr.Marcel Gärtner
Porodnicko-gynekologická klinika, FN Ostrava

This case report demonstrates achievement of satisfactionary effect of therapy in patient with intolerance of previously used anticholinergics.

Anticholinergics often present severe side effects which can limit their usage such as xerostomy, obstipation, dyspepsia, acomodation

disorders etc. The OAB therapy is recently influenced by newly developed drugs with prolonged release which are characterized

by reduction of incidence of adverse side effects.

Keywords: overactive bladder, farmacotherapy, anticholinergics

Published: June 4, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petzel M, Gärtner M. Intolerance to spasmolytic drugs in OAB treatment. Urol. praxi. 2012;13(3):122-124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Weiss Med Wkly 2009; 139(9-10): 146-151. Go to original source...
    2. Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011; 107(9): 1432-1440. Go to original source... Go to PubMed...
    3. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010; 105(1): 58-66. Go to original source... Go to PubMed...
    4. Chapple CR, Van Kerrebroeck PE, Junemann, et al. Comparison of fesoterodine and tolterodine in patiens with overactive bladder. BJU Int 2008; 102(9): 1128-1132. Go to original source... Go to PubMed...
    5. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71(5): 839-843. Go to original source... Go to PubMed...
    6. Kraus SR, Ruiz-Cerdá JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2011; 77(4): 1020. Go to original source...
    7. Corcos J, Angulo JC, Garely AD, Carlsson M, Gong J, Guan Z. Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group. Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Curr Med Res Opin. 2011; 27(5): 1059-1065. Epub 2011 Mar 23. Go to original source... Go to PubMed...
    8. 2006. Urinary incontinence: the management of urinary incontinence in women. Available: http://www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf.
    9. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A mediumterm analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997; 104: 988-993. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.